Comparison
Tirzepatide vs. VK2735
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Metabolic
Metabolic
CAS no.
2023788-19-2
no data
Molecular weight
4813 g/mol
no data
Half-life
116 h
no data
Sequence
YXEGTFTSDYSIYLDKIAQKAFVQWLIAGGPSSGAPPPSno data
Mechanism of action
Tirzepatide
Tirzepatide is a 39-amino-acid peptide acting as a dual agonist at the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors. Activation of both incretin receptors via G-protein-coupled signalling raises insulin secretion in a glucose-dependent manner, lowers glucagon secretion and delays gastric emptying. Centrally, satiety perception is modulated. A fatty-acid side chain binds to serum albumin and extends the half-life to about five days.
VK2735
VK2735 activates both the GLP-1 and the GIP receptor — a dual mechanism similar to that of tirzepatide, suppressing appetite and food intake.
Evidence base
Highest evidence
Human RCT
Human RCT
Studies
4
1
of which in humans
4
1
Effects recorded
4
2
Open conflicts
1
0
Documented adverse events
2
1
Legal status
Full entries
Frequently asked questions
- What is the difference between Tirzepatide and VK2735?
- Tirzepatide is classified as "Metabolic", while VK2735 is classified as "Metabolic". Tirzepatide: Synthetic peptide that simultaneously activates the GLP-1 and GIP receptor (dual agonist). Approved in the US and EU for type 2 diabetes (Mounjaro) and obesity (Zepbound). VK2735: VK2735 is a dual GLP-1/GIP receptor agonist from Viking Therapeutics, in development in both subcutaneous and oral forms for obesity. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Tirzepatide or VK2735?
- The highest available evidence level is "Human RCT" for Tirzepatide and "Human RCT" for VK2735. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Tirzepatide and VK2735 in Germany and the United States?
- Germany: Tirzepatide — Prescription, VK2735 — Unapproved. United States: Tirzepatide — Prescription, VK2735 — Unapproved. These are factual summaries with source and review date on the individual pages.